Abstract 5248: The use of reverse phase protein array (RPPA) to identify new tumor vulnerability and actionable drug targets against human cancer cell lines
Andrew Howell(Old Dominion University), Amy Tang(University of Southern California), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Julia D. Wulfkhule(George Mason University), Jonathan B. Baker(Eastern Virginia Medical School), Rosa I. Gallagher(George Mason University), Ashleigh Hannah(Old Dominion University)
Cited by 0
Related Papers
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
|The Lancet Oncology|2020|541
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
|Cancer Cell|2022|335
Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival
|Cancer Research|2007|252
Malignant Precursor Cells Pre-Exist in Human Breast DCIS and Require Autophagy for Survival
|PLoS ONE|2010|149
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
|Breast Cancer Research|2013|146